An interstitial hypothesis for breast cancer related lymphoedema.
Identifieur interne : 002C56 ( PubMed/Curation ); précédent : 002C55; suivant : 002C57An interstitial hypothesis for breast cancer related lymphoedema.
Auteurs : David O. Bates [Royaume-Uni]Source :
- Pathophysiology : the official journal of the International Society for Pathophysiology [ 0928-4680 ] ; 2010.
Abstract
Breast cancer related lymphoedema (BCRL), the chronically swollen arm of patients that have been treated for breast cancer, is no longer considered to be a result of lymphatic obstruction as recent studies have identified failing peripheral lymphatic function as a principal contributing factor. The aetiology and pathophysiology that results in this lymphatic failure is not clearly understood, but it can occur with minimal or even in some cases no damage to the axillary lymph nodes, and evidence suggests that some patients are pre-disposed to develop the disease, and have poor lymphatic function in their non-affected arms. It has been shown that interstitial forces such as hydrostatic pressure, and interstitial fluid velocity, can regulate both lymph flow, and lymph formation, and there is good evidence that interstitial forces are dysregulated in lymphoedema patients. Here I outline a hypothesis for how dysregulation of interstitial parameters could contribute to the generation of breast cancer related lymphoedema, by combining disparate strands of current evidence on the molecular and physiological control of interstitial and lymph flows. One mechanism by which lymphoedema could be generated is that a reduction in interstitial velocity results in increased VEGF-C production, which in low flow conditions, instead of acting on the lymphatics to increase pumping and lymphangiogenesis, acts on vasculature to increase fluid filtration. The resulting increase in interstitial pressure restores flow, but at the expense of increased volume and hence oedema. The evidence supporting the hypothesis and possible tests of it are presented and discussed.
DOI: 10.1016/j.pathophys.2009.10.006
PubMed: 19963358
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002C56
Links to Exploration step
pubmed:19963358Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">An interstitial hypothesis for breast cancer related lymphoedema.</title>
<author><name sortKey="Bates, David O" sort="Bates, David O" uniqKey="Bates D" first="David O" last="Bates">David O. Bates</name>
<affiliation wicri:level="1"><nlm:affiliation>Microvascular Research Laboratories, Bristol Heart Institute, Department of Physiology and Pharmacology, School of Veterinary Sciences, University of Bristol, Southwell Street, Bristol BS2 8EJ, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Microvascular Research Laboratories, Bristol Heart Institute, Department of Physiology and Pharmacology, School of Veterinary Sciences, University of Bristol, Southwell Street, Bristol BS2 8EJ</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2010">2010</date>
<idno type="RBID">pubmed:19963358</idno>
<idno type="pmid">19963358</idno>
<idno type="doi">10.1016/j.pathophys.2009.10.006</idno>
<idno type="wicri:Area/PubMed/Corpus">002C56</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002C56</idno>
<idno type="wicri:Area/PubMed/Curation">002C56</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002C56</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">An interstitial hypothesis for breast cancer related lymphoedema.</title>
<author><name sortKey="Bates, David O" sort="Bates, David O" uniqKey="Bates D" first="David O" last="Bates">David O. Bates</name>
<affiliation wicri:level="1"><nlm:affiliation>Microvascular Research Laboratories, Bristol Heart Institute, Department of Physiology and Pharmacology, School of Veterinary Sciences, University of Bristol, Southwell Street, Bristol BS2 8EJ, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Microvascular Research Laboratories, Bristol Heart Institute, Department of Physiology and Pharmacology, School of Veterinary Sciences, University of Bristol, Southwell Street, Bristol BS2 8EJ</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Pathophysiology : the official journal of the International Society for Pathophysiology</title>
<idno type="ISSN">0928-4680</idno>
<imprint><date when="2010" type="published">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Breast cancer related lymphoedema (BCRL), the chronically swollen arm of patients that have been treated for breast cancer, is no longer considered to be a result of lymphatic obstruction as recent studies have identified failing peripheral lymphatic function as a principal contributing factor. The aetiology and pathophysiology that results in this lymphatic failure is not clearly understood, but it can occur with minimal or even in some cases no damage to the axillary lymph nodes, and evidence suggests that some patients are pre-disposed to develop the disease, and have poor lymphatic function in their non-affected arms. It has been shown that interstitial forces such as hydrostatic pressure, and interstitial fluid velocity, can regulate both lymph flow, and lymph formation, and there is good evidence that interstitial forces are dysregulated in lymphoedema patients. Here I outline a hypothesis for how dysregulation of interstitial parameters could contribute to the generation of breast cancer related lymphoedema, by combining disparate strands of current evidence on the molecular and physiological control of interstitial and lymph flows. One mechanism by which lymphoedema could be generated is that a reduction in interstitial velocity results in increased VEGF-C production, which in low flow conditions, instead of acting on the lymphatics to increase pumping and lymphangiogenesis, acts on vasculature to increase fluid filtration. The resulting increase in interstitial pressure restores flow, but at the expense of increased volume and hence oedema. The evidence supporting the hypothesis and possible tests of it are presented and discussed.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">19963358</PMID>
<DateCreated><Year>2010</Year>
<Month>08</Month>
<Day>13</Day>
</DateCreated>
<DateCompleted><Year>2011</Year>
<Month>07</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>09</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0928-4680</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>17</Volume>
<Issue>4</Issue>
<PubDate><Year>2010</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Pathophysiology : the official journal of the International Society for Pathophysiology</Title>
<ISOAbbreviation>Pathophysiology</ISOAbbreviation>
</Journal>
<ArticleTitle>An interstitial hypothesis for breast cancer related lymphoedema.</ArticleTitle>
<Pagination><MedlinePgn>289-94</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pathophys.2009.10.006</ELocationID>
<Abstract><AbstractText>Breast cancer related lymphoedema (BCRL), the chronically swollen arm of patients that have been treated for breast cancer, is no longer considered to be a result of lymphatic obstruction as recent studies have identified failing peripheral lymphatic function as a principal contributing factor. The aetiology and pathophysiology that results in this lymphatic failure is not clearly understood, but it can occur with minimal or even in some cases no damage to the axillary lymph nodes, and evidence suggests that some patients are pre-disposed to develop the disease, and have poor lymphatic function in their non-affected arms. It has been shown that interstitial forces such as hydrostatic pressure, and interstitial fluid velocity, can regulate both lymph flow, and lymph formation, and there is good evidence that interstitial forces are dysregulated in lymphoedema patients. Here I outline a hypothesis for how dysregulation of interstitial parameters could contribute to the generation of breast cancer related lymphoedema, by combining disparate strands of current evidence on the molecular and physiological control of interstitial and lymph flows. One mechanism by which lymphoedema could be generated is that a reduction in interstitial velocity results in increased VEGF-C production, which in low flow conditions, instead of acting on the lymphatics to increase pumping and lymphangiogenesis, acts on vasculature to increase fluid filtration. The resulting increase in interstitial pressure restores flow, but at the expense of increased volume and hence oedema. The evidence supporting the hypothesis and possible tests of it are presented and discussed.</AbstractText>
<CopyrightInformation>Copyright © 2009 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bates</LastName>
<ForeName>David O</ForeName>
<Initials>DO</Initials>
<AffiliationInfo><Affiliation>Microvascular Research Laboratories, Bristol Heart Institute, Department of Physiology and Pharmacology, School of Veterinary Sciences, University of Bristol, Southwell Street, Bristol BS2 8EJ, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>BHF_BS/06/005/20340</GrantID>
<Agency>British Heart Foundation</Agency>
<Country>United Kingdom</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>12</Month>
<Day>05</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Pathophysiology</MedlineTA>
<NlmUniqueID>9433813</NlmUniqueID>
<ISSNLinking>0928-4680</ISSNLinking>
</MedlineJournalInfo>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Microvasc Res. 1977 Sep;14(2):191-204</RefSource>
<PMID Version="1">927217</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2008 Apr 10;26(11):1810-6</RefSource>
<PMID Version="1">18347007</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Vasc Surg. 1990 May;4(3):255-9</RefSource>
<PMID Version="1">2340247</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>EMBO J. 1996 Jan 15;15(2):290-98</RefSource>
<PMID Version="1">8617204</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lymphat Res Biol. 2003;1(2):121-32</RefSource>
<PMID Version="1">15624420</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Microvasc Res. 2006 Nov;72(3):161-71</RefSource>
<PMID Version="1">16876204</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Dec 27;357(26):2666-76</RefSource>
<PMID Version="1">18160686</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Breast Cancer Res Treat. 2009 Oct;117(3):549-57</RefSource>
<PMID Version="1">19052859</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Plast Reconstr Surg. 1989 Jun;83(6):939-45; discussion 946-7</RefSource>
<PMID Version="1">2727166</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 1989 Jul;86(14):5385-9</RefSource>
<PMID Version="1">2748592</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br Med J (Clin Res Ed). 1987 Jul 4;295(6589):3-4</RefSource>
<PMID Version="1">3113603</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Lymphology. 1973 Mar;6(1):35-51</RefSource>
<PMID Version="1">4691971</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Radiat Oncol Biol Phys. 1983 Dec;9(12):1807-13</RefSource>
<PMID Version="1">6662749</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Sci (Lond). 1993 Dec;85(6):737-46</RefSource>
<PMID Version="1">8287667</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Science. 1997 May 30;276(5317):1423-5</RefSource>
<PMID Version="1">9162011</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dev Biol. 1997 Aug 1;188(1):96-109</RefSource>
<PMID Version="1">9245515</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Physiol. 1998 Nov 15;513 ( Pt 1):225-33</RefSource>
<PMID Version="1">9782172</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer. 1998 Dec 15;83(12 Suppl American):2798-802</RefSource>
<PMID Version="1">9874400</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Exp Physiol. 1999 Mar;84(2):405-19</RefSource>
<PMID Version="1">10226181</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Nucl Med. 2000 Jun;25(6):451-64</RefSource>
<PMID Version="1">10836695</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Vasc Res. 2000 Nov-Dec;37(6):501-12</RefSource>
<PMID Version="1">11146404</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Vasc Res. 2001 Mar-Apr;38(2):176-86</RefSource>
<PMID Version="1">11316953</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2002 Jul;16(9):1041-9</RefSource>
<PMID Version="1">12087065</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2003 Apr 18;92(7):801-8</RefSource>
<PMID Version="1">12623882</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Br J Cancer. 2004 Feb 9;90(3):693-700</RefSource>
<PMID Version="1">14760386</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Sci (Lond). 2006 May;110(5):553-61</RefSource>
<PMID Version="1">16343054</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Biophys J. 2006 Jul 1;91(1):113-21</RefSource>
<PMID Version="1">16603487</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Physiol. 1896 May 5;19(4):312-26</RefSource>
<PMID Version="1">16992325</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Heart Circ Physiol. 2007 May;292(5):H2176-83</RefSource>
<PMID Version="1">17189348</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H709-18</RefSource>
<PMID Version="1">17400713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Eur J Surg Oncol. 2007 Nov;33(9):1052-60</RefSource>
<PMID Version="1">17499475</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Physiol. 2007 Aug 15;583(Pt 1):271-85</RefSource>
<PMID Version="1">17569739</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cardiovasc Res. 2008 May 1;78(2):315-23</RefSource>
<PMID Version="1">18065770</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int J Microcirc Clin Exp. 1992 Nov;11(4):359-73</RefSource>
<PMID Version="1">1459796</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<OtherID Source="NLM">PMC2923079</OtherID>
<OtherID Source="NLM">UKMS30638</OtherID>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year>
<Month>03</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2009</Year>
<Month>08</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2009</Year>
<Month>10</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>12</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>12</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>12</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19963358</ArticleId>
<ArticleId IdType="pii">S0928-4680(09)00116-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.pathophys.2009.10.006</ArticleId>
<ArticleId IdType="pmc">PMC2923079</ArticleId>
<ArticleId IdType="mid">UKMS30638</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C56 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002C56 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:19963358 |texte= An interstitial hypothesis for breast cancer related lymphoedema. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:19963358" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |